Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

Survey of Schistosomiasis in Saint Lucia: Evidence for Interruption of Transmission.

Gaspard J, Usey MM, Fredericks-James M, Sanchez-Martin MJ, Atkins L, Campbell CH, Corstjens PLAM, van Dam GJ, Colley DG, Secor WE.

Am J Trop Med Hyg. 2020 Apr;102(4):827-831. doi: 10.4269/ajtmh.19-0904.

2.

Environmental Predictors of Schistosomiasis Persistent Hotspots following Mass Treatment with Praziquantel.

Walker JW, Kittur N, Binder S, Castleman JD, Drake JM, Campbell CH, King CH, Colley DG.

Am J Trop Med Hyg. 2020 Feb;102(2):328-338. doi: 10.4269/ajtmh.19-0658.

3.

Modeling Approaches to Predicting Persistent Hotspots in SCORE Studies for Gaining Control of Schistosomiasis Mansoni in Kenya and Tanzania.

Shen Y, Sung MH, King CH, Binder S, Kittur N, Whalen CC, Colley DG.

J Infect Dis. 2020 Feb 18;221(5):796-803. doi: 10.1093/infdis/jiz529.

4.

Mapping Schistosoma mansoni endemicity in Rwanda: a critical assessment of geographical disparities arising from circulating cathodic antigen versus Kato-Katz diagnostics.

Clark NJ, Umulisa I, Ruberanziza E, Owada K, Colley DG, Ortu G, Campbell CH Jr, Ruzindana E, Lancaster W, Mbonigaba JB, Mbituyumuremyi A, Fenwick A, Soares Magalhaes RJ, Turate I.

PLoS Negl Trop Dis. 2019 Sep 30;13(9):e0007723. doi: 10.1371/journal.pntd.0007723. eCollection 2019 Sep.

5.

Five-Year Impact of Different Multi-Year Mass Drug Administration Strategies on Childhood Schistosoma mansoni-Associated Morbidity: A Combined Analysis from the Schistosomiasis Consortium for Operational Research and Evaluation Cohort Studies in the Lake Victoria Regions of Kenya and Tanzania.

Shen Y, Wiegand RE, Olsen A, King CH, Kittur N, Binder S, Zhang F, Whalen CC, Secor WE, Montgomery SP, Mwinzi PNM, Magnussen P, Kinung'hi S, Campbell CH, Colley DG.

Am J Trop Med Hyg. 2019 Dec;101(6):1336-1344. doi: 10.4269/ajtmh.19-0273.

6.

Persistent Hotspots in Schistosomiasis Consortium for Operational Research and Evaluation Studies for Gaining and Sustaining Control of Schistosomiasis after Four Years of Mass Drug Administration of Praziquantel.

Kittur N, King CH, Campbell CH, Kinung'hi S, Mwinzi PNM, Karanja DMS, N'Goran EK, Phillips AE, Gazzinelli-Guimaraes PH, Olsen A, Magnussen P, Secor WE, Montgomery SP, Utzinger J, Walker JW, Binder S, Colley DG.

Am J Trop Med Hyg. 2019 Sep;101(3):617-627. doi: 10.4269/ajtmh.19-0193.

7.

Multiple Praziquantel Treatments of Schistosoma mansoni Egg-Negative, CCA-Positive Schoolchildren in a Very Low Endemic Setting in Egypt Do Not Consistently Alter CCA Results.

Haggag AA, Casacuberta Partal M, Rabiee A, Abd Elaziz KM, Campbell CH, Colley DG, Ramzy RMR.

Am J Trop Med Hyg. 2019 Jun;100(6):1507-1511. doi: 10.4269/ajtmh.18-0961.

8.

Thirty-Day Daily Comparisons of Kato-Katz and CCA Assays of 45 Egyptian Children in Areas with Very Low Prevalence of Schistosoma mansoni.

Haggag AA, Rabiee A, Abd Elaziz KM, Campbell CH, Colley DG, Ramzy RMR.

Am J Trop Med Hyg. 2019 Mar;100(3):578-583. doi: 10.4269/ajtmh.18-0829.

9.

Translating preventive chemotherapy prevalence thresholds for Schistosoma mansoni from the Kato-Katz technique into the point-of-care circulating cathodic antigen diagnostic test.

Bärenbold O, Garba A, Colley DG, Fleming FM, Haggag AA, Ramzy RMR, Assaré RK, Tukahebwa EM, Mbonigaba JB, Bucumi V, Kebede B, Yibi MS, Meité A, Coulibaly JT, N'Goran EK, Tchuem Tchuenté LA, Mwinzi P, Utzinger J, Vounatsou P.

PLoS Negl Trop Dis. 2018 Dec 14;12(12):e0006941. doi: 10.1371/journal.pntd.0006941. eCollection 2018 Dec.

10.

Young Adults in Endemic Areas: An Untreated Group in Need of School-Based Preventive Chemotherapy for Schistosomiasis Control and Elimination.

Korir HK, Riner DK, Kavere E, Omondi A, Landry J, Kittur N, Ndombi EM, Ondigo BN, Secor WE, Karanja DMS, Colley DG.

Trop Med Infect Dis. 2018 Sep 5;3(3). pii: E100. doi: 10.3390/tropicalmed3030100.

11.

When Should the Emphasis on Schistosomiasis Control Move to Elimination?

Secor WE, Colley DG.

Trop Med Infect Dis. 2018 Aug 15;3(3). pii: E85. doi: 10.3390/tropicalmed3030085. Review.

12.

Impact of Mothers' Schistosomiasis Status During Gestation on Children's IgG Antibody Responses to Routine Vaccines 2 Years Later and Anti-Schistosome and Anti-Malarial Responses by Neonates in Western Kenya.

Ondigo BN, Muok EMO, Oguso JK, Njenga SM, Kanyi HM, Ndombi EM, Priest JW, Kittur N, Secor WE, Karanja DMS, Colley DG.

Front Immunol. 2018 Jun 18;9:1402. doi: 10.3389/fimmu.2018.01402. eCollection 2018.

13.

Functional Studies of T Regulatory Lymphocytes in Human Schistosomiasis in Western Kenya.

Ondigo BN, Ndombi EM, Nicholson SC, Oguso JK, Carter JM, Kittur N, Secor WE, Karanja DMS, Colley DG.

Am J Trop Med Hyg. 2018 Jun;98(6):1770-1781. doi: 10.4269/ajtmh.17-0966. Epub 2018 Apr 19.

14.

Effect of four rounds of annual school-wide mass praziquantel treatment for schistosoma mansoni control on schistosome-specific immune responses.

Ndombi EM, Abudho B, Kittur N, Carter JM, Korir H, Riner DK, Ochanda H, Lee YM, Secor WE, Karanja DM, Colley DG.

Parasite Immunol. 2018 Jun;40(6):e12530. doi: 10.1111/pim.12530. Epub 2018 Apr 29.

15.

Impact of Four Years of Annual Mass Drug Administration on Prevalence and Intensity of Schistosomiasis among Primary and High School Children in Western Kenya: A Repeated Cross-Sectional Study.

Abudho BO, Ndombi EM, Guya B, Carter JM, Riner DK, Kittur N, Karanja DMS, Secor WE, Colley DG.

Am J Trop Med Hyg. 2018 May;98(5):1397-1402. doi: 10.4269/ajtmh.17-0908. Epub 2018 Mar 8.

16.

Latent class analysis to evaluate performance of point-of-care CCA for low-intensity Schistosoma mansoni infections in Burundi.

Clements MN, Corstjens PLAM, Binder S, Campbell CH Jr, de Dood CJ, Fenwick A, Harrison W, Kayugi D, King CH, Kornelis D, Ndayishimiye O, Ortu G, Lamine MS, Zivieri A, Colley DG, van Dam GJ.

Parasit Vectors. 2018 Feb 23;11(1):111. doi: 10.1186/s13071-018-2700-4.

17.

Historical perspective: Revisiting the St. Lucia Project, a multi-year comparison trial of schistosomiasis control strategies.

Ivy JA, King CH, Cook JA, Colley DG.

PLoS Negl Trop Dis. 2018 Jan 31;12(1):e0006223. doi: 10.1371/journal.pntd.0006223. eCollection 2018 Jan. No abstract available.

18.

New Tools for Old Questions: How Strictly Human Are "Human Schistosomes"-And Does It Matter?

Colley DG, Loker ES.

J Infect Dis. 2018 Jul 2;218(3):344-346. doi: 10.1093/infdis/jiy030. No abstract available. Erratum in: J Infect Dis. 2018 Aug 14;218(6):1014.

PMID:
29365121
19.

Defining Persistent Hotspots: Areas That Fail to Decrease Meaningfully in Prevalence after Multiple Years of Mass Drug Administration with Praziquantel for Control of Schistosomiasis.

Kittur N, Binder S, Campbell CH, King CH, Kinung'hi S, Olsen A, Magnussen P, Colley DG.

Am J Trop Med Hyg. 2017 Dec;97(6):1810-1817. doi: 10.4269/ajtmh.17-0368. Epub 2017 Sep 21.

20.

Protocol and baseline data for a multi-year cohort study of the effects of different mass drug treatment approaches on functional morbidities from schistosomiasis in four African countries.

Shen Y, King CH, Binder S, Zhang F, Whalen CC, Evan Secor W, Montgomery SP, Mwinzi PNM, Olsen A, Magnussen P, Kinung'hi S, Phillips AE, Nalá R, Ferro J, Aurelio HO, Fleming F, Garba A, Hamidou A, Fenwick A, Campbell CH Jr, Colley DG.

BMC Infect Dis. 2017 Sep 29;17(1):652. doi: 10.1186/s12879-017-2738-5.

21.

Building a global schistosomiasis alliance: an opportunity to join forces to fight inequality and rural poverty.

Savioli L, Albonico M, Colley DG, Correa-Oliveira R, Fenwick A, Green W, Kabatereine N, Kabore A, Katz N, Klohe K, LoVerde PT, Rollinson D, Stothard JR, Tchuem Tchuenté LA, Waltz J, Zhou XN.

Infect Dis Poverty. 2017 Mar 23;6(1):65. doi: 10.1186/s40249-017-0280-8. Review.

22.

Schistosomiasis is more prevalent than previously thought: what does it mean for public health goals, policies, strategies, guidelines and intervention programs?

Colley DG, Andros TS, Campbell CH Jr.

Infect Dis Poverty. 2017 Mar 22;6(1):63. doi: 10.1186/s40249-017-0275-5. Review.

23.

Countrywide Reassessment of Schistosoma mansoni Infection in Burundi Using a Urine-Circulating Cathodic Antigen Rapid Test: Informing the National Control Program.

Ortu G, Ndayishimiye O, Clements M, Kayugi D, Campbell CH, Lamine MS, Zivieri A, Magalhaes RS, Binder S, King CH, Fenwick A, Colley DG, Jourdan PM.

Am J Trop Med Hyg. 2017 Mar;96(3):664-673. doi: 10.4269/ajtmh.16-0671. Epub 2017 Apr 6.

24.

Schistosoma mansoni Infection Can Jeopardize the Duration of Protective Levels of Antibody Responses to Immunizations against Hepatitis B and Tetanus Toxoid.

Riner DK, Ndombi EM, Carter JM, Omondi A, Kittur N, Kavere E, Korir HK, Flaherty B, Karanja D, Colley DG.

PLoS Negl Trop Dis. 2016 Dec 7;10(12):e0005180. doi: 10.1371/journal.pntd.0005180. eCollection 2016 Dec.

25.

A call to strengthen the global strategy against schistosomiasis and soil-transmitted helminthiasis: the time is now.

Lo NC, Addiss DG, Hotez PJ, King CH, Stothard JR, Evans DS, Colley DG, Lin W, Coulibaly JT, Bustinduy AL, Raso G, Bendavid E, Bogoch II, Fenwick A, Savioli L, Molyneux D, Utzinger J, Andrews JR.

Lancet Infect Dis. 2017 Feb;17(2):e64-e69. doi: 10.1016/S1473-3099(16)30535-7. Epub 2016 Nov 30. Review.

26.

Gaining and sustaining schistosomiasis control: study protocol and baseline data prior to different treatment strategies in five African countries.

Ezeamama AE, He CL, Shen Y, Yin XP, Binder SC, Campbell CH Jr, Rathbun S, Whalen CC, N'Goran EK, Utzinger J, Olsen A, Magnussen P, Kinung'hi S, Fenwick A, Phillips A, Ferro J, Karanja DM, Mwinzi PN, Montgomery S, Secor WE, Hamidou A, Garba A, King CH, Colley DG.

BMC Infect Dis. 2016 May 26;16:229. doi: 10.1186/s12879-016-1575-2.

27.

Comparison of Schistosoma mansoni Prevalence and Intensity of Infection, as Determined by the Circulating Cathodic Antigen Urine Assay or by the Kato-Katz Fecal Assay: A Systematic Review.

Kittur N, Castleman JD, Campbell CH, King CH, Colley DG.

Am J Trop Med Hyg. 2016 Mar;94(3):605-610. doi: 10.4269/ajtmh.15-0725. Epub 2016 Jan 11. Review.

28.

Workshop report: Schistosomiasis vaccine clinical development and product characteristics.

Mo AX, Colley DG.

Vaccine. 2016 Feb 17;34(8):995-1001. doi: 10.1016/j.vaccine.2015.12.032. Epub 2015 Dec 22.

PMID:
26721329
29.

Additional Evaluation of the Point-of-Contact Circulating Cathodic Antigen Assay for Schistosoma mansoni Infection.

Mwinzi PN, Kittur N, Ochola E, Cooper PJ, Campbell CH Jr, King CH, Colley DG.

Front Public Health. 2015 Mar 19;3:48. doi: 10.3389/fpubh.2015.00048. eCollection 2015.

30.
31.

Immunology of human schistosomiasis.

Colley DG, Secor WE.

Parasite Immunol. 2014 Aug;36(8):347-57. doi: 10.1111/pim.12087. Review.

32.

Human schistosomiasis.

Colley DG, Bustinduy AL, Secor WE, King CH.

Lancet. 2014 Jun 28;383(9936):2253-64. doi: 10.1016/S0140-6736(13)61949-2. Epub 2014 Apr 1. Review.

33.

A five-country evaluation of a point-of-care circulating cathodic antigen urine assay for the prevalence of Schistosoma mansoni.

Colley DG, Binder S, Campbell C, King CH, Tchuem Tchuenté LA, N'Goran EK, Erko B, Karanja DMS, Kabatereine NB, van Lieshout L, Rathbun S.

Am J Trop Med Hyg. 2013 Mar;88(3):426-432. doi: 10.4269/ajtmh.12-0639. Epub 2013 Jan 21.

34.

Study and implementation of urogenital schistosomiasis elimination in Zanzibar (Unguja and Pemba islands) using an integrated multidisciplinary approach.

Knopp S, Mohammed KA, Ali SM, Khamis IS, Ame SM, Albonico M, Gouvras A, Fenwick A, Savioli L, Colley DG, Utzinger J, Person B, Rollinson D.

BMC Public Health. 2012 Oct 30;12:930. doi: 10.1186/1471-2458-12-930.

35.

Time to set the agenda for schistosomiasis elimination.

Rollinson D, Knopp S, Levitz S, Stothard JR, Tchuem Tchuenté LA, Garba A, Mohammed KA, Schur N, Person B, Colley DG, Utzinger J.

Acta Trop. 2013 Nov;128(2):423-40. doi: 10.1016/j.actatropica.2012.04.013. Epub 2012 May 10. Review.

PMID:
22580511
36.

Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review.

King CH, Olbrych SK, Soon M, Singer ME, Carter J, Colley DG.

PLoS Negl Trop Dis. 2011 Sep;5(9):e1321. doi: 10.1371/journal.pntd.0001321. Epub 2011 Sep 20. Review.

37.

Increases in levels of schistosome-specific immunoglobulin E and CD23(+) B cells in a cohort of Kenyan children undergoing repeated treatment and reinfection with Schistosoma mansoni.

Black CL, Muok EM, Mwinzi PN, Carter JM, Karanja DM, Secor WE, Colley DG.

J Infect Dis. 2010 Aug 15;202(3):399-405. doi: 10.1086/653828.

38.

Influence of exposure history on the immunology and development of resistance to human Schistosomiasis mansoni.

Black CL, Mwinzi PN, Muok EM, Abudho B, Fitzsimmons CM, Dunne DW, Karanja DM, Secor WE, Colley DG.

PLoS Negl Trop Dis. 2010 Mar 23;4(3):e637. doi: 10.1371/journal.pntd.0000637.

39.

Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni.

Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, Wynn NB, Mutuku MW, Karanja DM, Colley DG, Black CL, Secor WE, Mkoji GM, Loker ES.

PLoS Negl Trop Dis. 2009 Aug 18;3(8):e504. doi: 10.1371/journal.pntd.0000504.

40.

Relative imbalance between T regulatory cells and activated T cells in mice with differential morbidity in chronic Schistosoma mansoni infections.

Watanabe K, Carter JM, Neely-Burnam M, Colley DG.

Parasite Immunol. 2009 Aug;31(8):440-6. doi: 10.1111/j.1365-3024.2009.01127.x.

41.

Short report: Childhood coinfections with Plasmodium falciparum and Schistosoma mansoni result in lower percentages of activated T cells and T regulatory memory cells than schistosomiasis only.

Muok EM, Mwinzi PN, Black CL, Carter JM, Ng'ang'a ZW, Gicheru MM, Secor WE, Karanja DM, Colley DG.

Am J Trop Med Hyg. 2009 Mar;80(3):475-8. Erratum in: Am J Trop Med Hyg. 2009 Aug;81(2):370. Am J Trop Med Hyg. 2009 May;80(5):877. Mouk, Erick M O [corrected to Muok, Erick M O].

42.

Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya.

Black CL, Steinauer ML, Mwinzi PN, Evan Secor W, Karanja DM, Colley DG.

Trop Med Int Health. 2009 Apr;14(4):450-7. doi: 10.1111/j.1365-3156.2009.02234.x. Epub 2009 Feb 14.

43.

Association of the gene polymorphisms IFN-gamma +874, IL-13 -1055 and IL-4 -590 with patterns of reinfection with Schistosoma mansoni.

Gatlin MR, Black CL, Mwinzi PN, Secor WE, Karanja DM, Colley DG.

PLoS Negl Trop Dis. 2009;3(2):e375. doi: 10.1371/journal.pntd.0000375. Epub 2009 Feb 3.

44.
45.

A schistosomiasis research agenda.

Colley DG, Secor WE.

PLoS Negl Trop Dis. 2007 Nov 26;1(3):e32.

46.

T regulatory cell levels decrease in people infected with Schistosoma mansoni on effective treatment.

Watanabe K, Mwinzi PN, Black CL, Muok EM, Karanja DM, Secor WE, Colley DG.

Am J Trop Med Hyg. 2007 Oct;77(4):676-82.

47.

Early responses associated with chronic pathology in murine schistosomiasis.

Cêtre-Sossah CB, Montesano MA, Freeman GL Jr, Willard MT, Colley DG, Secor WE.

Parasite Immunol. 2007 May;29(5):241-9.

48.

Higher percentages of circulating mast cell precursors correlate with susceptibility to reinfection with Schistosoma mansoni.

Ganley-Leal LM, Mwinzi PN, Cetre-Sossah CB, Andove J, Hightower AW, Karanja DM, Colley DG, Secor WE.

Am J Trop Med Hyg. 2006 Dec;75(6):1053-7.

PMID:
17172364
49.

Schistosomiasis vaccine:research to development.

Bergquist NR, Colley DG.

Parasitol Today. 1998 Mar;14(3):99-104.

PMID:
17040715
50.

Correlation between eosinophils and protection against reinfection with Schistosoma mansoni and the effect of human immunodeficiency virus type 1 coinfection in humans.

Ganley-Leal LM, Mwinzi PN, Cetre-Sossah CB, Andove J, Hightower AW, Karanja DM, Colley DG, Secor WE.

Infect Immun. 2006 Apr;74(4):2169-76.

Supplemental Content

Loading ...
Support Center